Gilead's Biktarvy Set For EU Approval
Executive Summary
A combination therapy – Gilead Science’s Biktarvy – a hybrid medicine and a generic can look forward to EU approval after getting the OK from the EMA’s drug evaluation committee last week.
You may also be interested in...
Gilead's Biktarvy Profile Rises As CHMP Backs Daily HIV Therapy
Biktarvy's strength in battle against ViiV Healthcare's dolutegravir franchises is seen as a 'double-edged sword' for Gilead in HIV contest amid foreseen old drug 'cannibalization'.